Researching Modifiable and Non-Modifiable Risk Factors Linked to Cognitive Resilience in Alzheimer’s Disease
What do we do?
Our lab focuses on clarifying how alterations in the brain and other biomolecules (such as cerebrospinal fluid β-amyloid) place some cognitively-normal individuals on a pernicious trajectory that culminates in Alzheimer’s dementia. In this context, we are also interested in discovering new knowledge concerning the modulation of the link between brain changes and cognitive decline by both modifiable (e.g., cognitively-stimulating activities, physical exercise) and non-modifiable (e.g., genetic vulnerability) factors.
We use many techniques in our research, including but not limited to:
This is an accordion element with a series of buttons that open and close related content panels.
MRI and PET Imaging
Cerebrospinal Fluid Collection
Maximal Exercise Testing
Physical Activity Monitoring
We are a part of the larger Wisconsin Alzheimer’s Disease Research Program, which includes both the Wisconsin Alzheimer’s Disease Research Center and the Wisconsin Alzheimer’s Institute.
Our offices are located on UW Madison’s campus within the UW Hospital. The majority of our research is conducted within the UW Hospital, the Waisman Center, the Wisconsin Institute for Medical Research, and the YMCA.
Clayton McIntyre’s Manuscript Accepted for Publication
Former lab student, Clayton McIntyre, had his manuscript titled, “Insulin Homeostasis Mediates the Relationship Between Cardiorespiratory Fitness and Cognitive Speed in Aging Adults Journal of Alzheimer’s Disease” accepted for publication in the Journal of Alzeimer’s Disease …March 13, 2023
John Omelina Offered Seat at Doctor of Osteopathic Medicine Program
Former lab member John Omelina has been offered a seat in the Doctor of Osteopathic Medicine program at Touro University Nevada for the class of 2027. This is absolutely phenomenal and we are so proud! …February 14, 2023
Chinenye Odo Passes Medical Board Licensing Examination
Chinenye Odo passed her United States Medical Board Licensing Examination. This is a phenomenal accomplishment and we are beyond proud. Congratulations, Chinenye!February 3, 2023
Ira Invited to Give Oral Presentation at International Conference
Ira Frahmand has been invited to give an oral presentation at the AD/PD 2023 International Conference for her abstract “Alzheimer’s disease biomarker status is associated with KLOTHO genotype but not klotho protein levels in an …December 1, 2022
- More News